Home › Glycogen Storage Disease Type II › Pennsylvania › Philadelphia
Glycogen Storage Disease Type II clinical trials in Philadelphia, PA
4 studies for Glycogen Storage Disease Type II are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
RecruitingPhase 1/2
- Hospital of the University of Pennsylvania, Philadelphia
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
RecruitingPhase 2
- University of Pennsylvania, Philadelphia
Pompe Disease Registry Protocol
RecruitingObservational study
- Children's Hospital of Philadelphia HUP Medical Genetics- Site Number : 840089, Philadelphia
- Children's Hospital of Philadelphia- Site Number : 840034, Philadelphia
A Global Prospective Observational Registry of Patients With Pompe Disease
RecruitingObservational study
- University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
Glycogen Storage Disease Type II trials in other cities
- Durham, NC8 studies
- Irvine, CA5 studies
- Arlington, VA5 studies
- St. Louis, MO5 studies
- Atlanta, GA4 studies
- Pittsburgh, PA4 studies
- New York City, NY4 studies
- Cincinnati, OH3 studies
- Indianapolis, IN3 studies
- Jacksonville, FL3 studies
- Phoenix, AZ3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.